Comment

ZAXINE® (rifaximine) is now covered with special authorization on all provincial formularies, the NIHB and the Yukon Drug Programs Formulary in Canada!

Lupin Pharma Canada is pleased to announce that ZAXINE® is now listed across all Canadian provinces with the recent addition of PEI coverage.

The coverage criteria for PEI (special authority criteria) as of July 23, 2018 are:

For reducing the risk of overt hepatic encephalopathy (HE) recurrence (i.e., ≥2 episodes) in patients who meet the following criteria:

  • Patients are unable to achieve adequate control of HE recurrence with maximal tolerated dose of lactulose alone.

  • Must be used in combination with maximal tolerated doses of lactulose.

  • For patients not maintained on lactulose, information is required regarding the nature of the patient’s intolerance to lactulose.

For more information, click here.

Comment

Comment

ZAXINE® (rifaximin) now covered by British Columbia Pharmacare!

Lupin Pharma Canada is pleased to announce that ZAXINE is listed with special authority criteria as February 6, 2018.
The coverage criteria are as follows:

For reducing the risk of overt hepatic encephalopathy (HE) recurrence in patients who meet the following criteria:

  • Have been hospitalized with HE associated with cirrhosis of the liver; AND
  • Are unable to achieve adequate control, despite taking the maximum tolerated dose of lactulose; AND
  • Rifaximin must be prescribed by an internal medicine specialist or a gastroenterologist.

Rifaximin should be used in combination with a maximal tolerated dose of lactulose.

For more information, click here

Comment

Comment

Lupin and Salix Announce Exclusive Distribution Agreement for Canada Zaxine®, Relistor® and Other Gastroenterology Products

September 12, 2014 Lupin Limited (Lupin) and Salix Pharmaceuticals, Inc. (Salix) announced today that they have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada. This includes immediate rights to distribute Zaxine® (rifaximin) 550 mg tablets for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age or
older, and Relistor® Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond 4 months has not been studied. Additionally, the agreement includes future dosage forms, strengths, and indications for such products. Under the agreement, Lupin also has the option to exclusively market, distribute and sell other gastroenterology products in Salix’s Canadian pipeline once approved by Health
Canada.

For more information, click here

Comment